In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forward Pharma A/S

http://forward-pharma.com/

Latest From Forward Pharma A/S

Tech Transfer Roundup: MD Anderson Tackles Cancer In Alliances With UroGen, Xencor, Obsidian

In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.

Deals Business Strategies

Merck & Co. Looks To Artiva’s Off-The-Shelf Cell Therapy Technologies

Deal Snapshot: Pharma places $30m upfront wager on biotech’s allogeneic natural killer cell and chimeric antigen receptor technologies, with hopes for solid tumor cell therapies.

Deals ImmunoOncology

Deals Of The Year: Cast Your Vote For Top Alliance Of 2017

It's time for In Vivo's10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.) First up, the top five picks for most significant strategic alliance of 2017.

Deals Financing

Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes

ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.

Life Cycle Management Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
UsernamePublicRestriction

Register